Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

11/12/24 10:32:12 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $GLUE alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 MONTE ROSA THERAPEUTICS INC COMMON STOCK Cusip #61225M102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #61225M102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,100,211 Item 6: 0 Item 7: 5,101,413 Item 8: 0 Item 9: 5,101,413 Item 11: 8.312% Item 12: HC Cusip #61225M102 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 5,101,413 Item 8: 0 Item 9: 5,101,413 Item 11: 8.312% Item 12: IN Item 1(a). Name of Issuer: MONTE ROSA THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 321 HARRISON AVENUE, SUITE 900 BOSTON, MA 02118 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 61225M102 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 5,101,413 (b) Percent of Class: 8.312% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 5,101,413 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of MONTE ROSA THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of MONTE ROSA THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of MONTE ROSA THERAPEUTICS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $GLUE alert in real time by email

Recent Analyst Ratings for

$GLUE

Date	Price Target	Rating	Analyst
12/19/2024	$14.00 → $11.00	Overweight → Equal Weight	Wells Fargo
2/15/2024	$11.00	Outperform	Wedbush
1/3/2023	$18.00	Equal Weight → Overweight	Wells Fargo
10/13/2022	$22.00	Buy	UBS
8/15/2022	$20.00	Buy	Jefferies
4/28/2022	$19.00	Neutral	Credit Suisse
2/10/2022	$19.00	Equal-Weight	Wells Fargo
10/14/2021	$20.00	Mkt Perform	SVB Leerink

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

11/12/24 10:32:12 AM ET

$GLUE

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $GLUE alert in real time by email

Recent Analyst Ratings for

$GLUE

Date	Price Target	Rating	Analyst
12/19/2024	$14.00 → $11.00	Overweight → Equal Weight	Wells Fargo
2/15/2024	$11.00	Outperform	Wedbush
1/3/2023	$18.00	Equal Weight → Overweight	Wells Fargo
10/13/2022	$22.00	Buy	UBS
8/15/2022	$20.00	Buy	Jefferies
4/28/2022	$19.00	Neutral	Credit Suisse
2/10/2022	$19.00	Equal-Weight	Wells Fargo
10/14/2021	$20.00	Mkt Perform	SVB Leerink

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$GLUE

Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$GLUE

$GLUE
Insider Trading

SEC Form 4 filed by Director Behbahani Ali

SEC Form 4 filed by Director Hughes Eric A

SEC Form 4 filed by Director Siu Christine

$GLUE
Press Releases

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

$GLUE
SEC Filings

SEC Form SCHEDULE 13G filed by Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.

$GLUE
Analyst Ratings

Monte Rosa Therapeutics downgraded by Wells Fargo with a new price target

Wedbush initiated coverage on Monte Rosa Therapeutics with a new price target

Monte Rosa Therapeutics upgraded by Wells Fargo with a new price target

$GLUE
Insider Purchases

Director Leo Chandra P. bought $58,383 worth of shares (10,000 units at $5.84) (SEC Form 4)

$GLUE
Leadership Updates

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

$GLUE
Financials

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

$GLUE
Large Ownership Changes